GENMAB - Dusseldorf Stock Exchang (GE9 DU) stock market data APIs
€244.5225
-1.81(-0.7%)
as of October 31, 2025
Try our APIs with
free plan!
GENMAB - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GE9.DU.
Prev. Close
244.5225
Open
242.7147
High
247.2191
Low
242.7147
52 wk Range
157-286.8
Market Cap
22 148 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GENMAB - Dusseldorf Stock Exchang data using free add-ons & libraries
Get GENMAB - Dusseldorf Stock Exchang Fundamental Data
GENMAB - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: 31.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GENMAB - Dusseldorf Stock Exchang News
New
H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) on October 21 with a $40 price t...
How Recent Partnerships Are Shaping Genmab’s Value in 2025
If you have Genmab in your portfolio or you are eyeing the stock for your next move, now is the perfect time to take a closer look. The biotech sector is often a rollercoaster, and Genmab has not been...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Genmab A/S Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Genmab A/S Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed obj...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
